An update on phase I study of dose-escalating imatinib mesylate plus standard-dosed temozolomide for the treatment of patients with malignant glioma.
Publication
, Conference
Sathornsumetee, S; Reardon, DA; Quinn, JA; Rich, JN; Vredenburgh, JJ; Desjardins, A; Gururangan, S; Egorin, M; Salvado, A; Friedman, HS
Published in: JOURNAL OF CLINICAL ONCOLOGY
June 20, 2006
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
ISSN
0732-183X
Publication Date
June 20, 2006
Volume
24
Issue
18
Start / End Page
72S / 72S
Location
Atlanta, GA
Publisher
AMER SOC CLINICAL ONCOLOGY
Conference Name
42nd Annual Meeting of the American-Society-of-Clinical-Oncology
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Sathornsumetee, S., Reardon, D. A., Quinn, J. A., Rich, J. N., Vredenburgh, J. J., Desjardins, A., … Friedman, H. S. (2006). An update on phase I study of dose-escalating imatinib mesylate plus standard-dosed temozolomide for the treatment of patients with malignant glioma. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 24, pp. 72S-72S). Atlanta, GA: AMER SOC CLINICAL ONCOLOGY.
Sathornsumetee, S., D. A. Reardon, J. A. Quinn, J. N. Rich, J. J. Vredenburgh, A. Desjardins, S. Gururangan, M. Egorin, A. Salvado, and H. S. Friedman. “An update on phase I study of dose-escalating imatinib mesylate plus standard-dosed temozolomide for the treatment of patients with malignant glioma.” In JOURNAL OF CLINICAL ONCOLOGY, 24:72S-72S. AMER SOC CLINICAL ONCOLOGY, 2006.
Sathornsumetee S, Reardon DA, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, et al. An update on phase I study of dose-escalating imatinib mesylate plus standard-dosed temozolomide for the treatment of patients with malignant glioma. In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2006. p. 72S-72S.
Sathornsumetee, S., et al. “An update on phase I study of dose-escalating imatinib mesylate plus standard-dosed temozolomide for the treatment of patients with malignant glioma.” JOURNAL OF CLINICAL ONCOLOGY, vol. 24, no. 18, AMER SOC CLINICAL ONCOLOGY, 2006, pp. 72S-72S.
Sathornsumetee S, Reardon DA, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Gururangan S, Egorin M, Salvado A, Friedman HS. An update on phase I study of dose-escalating imatinib mesylate plus standard-dosed temozolomide for the treatment of patients with malignant glioma. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2006. p. 72S-72S.
Published In
JOURNAL OF CLINICAL ONCOLOGY
ISSN
0732-183X
Publication Date
June 20, 2006
Volume
24
Issue
18
Start / End Page
72S / 72S
Location
Atlanta, GA
Publisher
AMER SOC CLINICAL ONCOLOGY
Conference Name
42nd Annual Meeting of the American-Society-of-Clinical-Oncology
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences